Skip to main content
A
NYSE Life Sciences

Agilent to Acquire Global Pathology Leader Biocare Medical, Expanding Life Sciences Portfolio

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
8
Price
$116.408
Mkt Cap
$32.519B
52W Low
$96.43
52W High
$160.27
Market data snapshot near publication time

summarizeSummary

Agilent Technologies announced its intent to acquire Biocare Medical, a recognized leader in clinical and research pathology solutions. This strategic acquisition is a significant move for Agilent, expanding its presence and capabilities within the life sciences sector, specifically in the high-growth pathology market. While financial terms were not disclosed in the headline, acquiring a 'global leader' suggests a material investment aimed at enhancing Agilent's product portfolio and market reach. This news follows Agilent's recent Q1 2026 financial results, indicating continued strategic growth initiatives. Traders will be watching for further details on the acquisition's financial impact and integration plans.

في وقت هذا الإعلان، كان A يتداول عند ‏١١٦٫٤١ US$ في NYSE ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ٣٢٫٥ مليار US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ‏٩٦٫٤٣ US$ و‏١٦٠٫٢٧ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية إيجابية وبدرجة أهمية ٨ من 10. المصدر: Dow Jones Newswires.


show_chartPrice Chart

Share this article

Copied!

feed A - Latest Insights

A
Mar 26, 2026, 8:49 AM EDT
Source: dpa-AFX
Importance Score:
7
A
Mar 20, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
A
Mar 10, 2026, 5:48 AM EDT
Source: Reuters
Importance Score:
8
A
Mar 09, 2026, 3:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
A
Feb 25, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
A
Jan 23, 2026, 7:00 AM EST
Filing Type: PRE 14A
Importance Score:
8